Although it cannot be concluded that α-SMA-positive cells are simply tumor-restraining CAFs (see the Section 1), targeting PRRX1 can be a promising strategy for reprograming tumor-promoting subtype of CAFs to tumor-restraining subtype of CAFs. This evidence concerns the gene ACTA1 and neoplasm.